P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus

Epilepsy and Behavior

Volumn 49, Issue , 2015, Pages 8-12

  Henshall, David C ^a   Engel, Tobias ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Adenosine; Epileptogenesis; Hippocampal sclerosis; Purinoceptor; Super refractory status epilepticus

Indexed keywords

INTERLEUKIN 1BETA; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2X RECEPTOR; PURINERGIC P2X RECEPTOR ANTAGONIST;

ASTROCYTE; CELL ACTIVATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; EPILEPTIC STATE; EPILEPTOGENESIS; GAIN OF FUNCTION MUTATION; HUMAN; INFANTILE SPASM; MICROGLIA; NERVE CELL EXCITABILITY; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMITTER RELEASE; NONHUMAN; P2RX7 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; ANIMAL; DRUG EFFECTS; HIPPOCAMPUS; INFLAMMATION; MALE; METABOLISM; MOUSE; NERVE CELL; RAT; STATUS EPILEPTICUS; TREATMENT OUTCOME;

ANIMALS; HIPPOCAMPUS; INFLAMMATION; MALE; MICE; NEURONS; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2X; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84938983879     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.02.031     Document Type: Review

References (51)

1. Chen J.W., Wasterlain C.G. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006, 5:246-256.
2. Shorvon S. The treatment of status epilepticus. Curr Opin Neurol 2011, 24:165-170.
3. Trinka E., Hofler J., Zerbs A. Causes of status epilepticus. Epilepsia 2012, 53(Suppl. 4):127-138.
4. Brophy G.M., Bell R., Claassen J., Alldredge B., Bleck T.P., Glauser T., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012, 17:3-23.
5. Wasterlain C.G., Liu H., Naylor D.E., Thompson K.W., Suchomelova L., Niquet J., et al. Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 2009, 50(Suppl. 12):16-18.
6. Shorvon S., Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011, 134:2802-2818.
7. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 2008, 7:575-590.
8. Dale N., Frenguelli B.G. Release of adenosine and ATP during ischemia and epilepsy. Curr Neuropharmacol 2009, 7:160-179.
9. Idzko M., Ferrari D., Eltzschig H.K. Nucleotide signalling during inflammation. Nature 2014, 509:310-317.
10. Engel T., Jimenez-Pacheco A., Miras-Portugal M.T., Diaz-Hernandez M., Henshall D.C. P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control. Int J Physiol Pathophysiol Pharmacol 2012, 4:174-187.
11. Henshall D.C., Diaz-Hernandez M., Miras-Portugal M.T., Engel T. P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 2013, 7:237.
12. Henshall D.C., Clark R.S., Adelson P.D., Chen M., Watkins S.C., Simon R.P. Alterations in bcl-2 and caspase gene family protein expression in human temporal lobe epilepsy. Neurology 2000, 55:250-257.
13. Allan S.M., Tyrrell P.J., Rothwell N.J. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005, 5:629-640.
14. Vezzani A., French J., Bartfai T., Baram T.Z. The role of inflammation in epilepsy. Nat Rev Neurol 2011, 7:31-40.
15. Johnson M.R., Behmoaras J., Bottolo L., Krishnan M.L., Pernhorst K., Santoscoy P.L., et al. Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nat Commun 2015, 6:6031.
16. Skaper S.D., Debetto P., Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 2010, 24:337-345.
17. Sperlagh B., Illes P. P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci 2014, 35:537-547.
18. Coddou C., Yan Z., Obsil T., Huidobro-Toro J.P., Stojilkovic S.S. Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 2011, 63:641-683.
19. Monif M., Reid C.A., Powell K.L., Smart M.L., Williams D.A. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci 2009, 29:3781-3791.
20. Facci L., Barbierato M., Marinelli C., Argentini C., Skaper S.D., Giusti P. Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1beta release. Sci Rep 2014, 4:6824.
21. Maroso M., Balosso S., Ravizza T., Liu J., Aronica E., Iyer A.M., et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010, 16:413-419.
22. Armstrong J.N., Brust T.B., Lewis R.G., MacVicar B.A. Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci 2002, 22:5938-5945.
23. Sperlagh B., Kofalvi A., Deuchars J., Atkinson L., Milligan C.J., Buckley N.J., et al. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem 2002, 81:1196-1211.
24. Lopatar J., Dale N., Frenguelli B.G. Minor contribution of ATP P2 receptors to electrically-evoked electrographic seizure activity in hippocampal slices: evidence from purine biosensors and P2 receptor agonists and antagonists. Neuropharmacology 2011, 61:25-34.
25. Maraula G., Lana D., Coppi E., Gentile F., Mello T., Melani A., et al. The selective antagonism of P2X7 and P2Y1 receptors prevents synaptic failure and affects cell proliferation induced by oxygen and glucose deprivation in rat dentate gyrus. PLoS One 2014, 9:e115273.
26. Yu Y., Ugawa S., Ueda T., Ishida Y., Inoue K., Kyaw Nyunt A., et al. Cellular localization of P2X7 receptor mRNA in the rat brain. Brain Res 2008, 1194:45-55.
27. Engel T., Gomez-Villafuertes R., Tanaka K., Mesuret G., Sanz-Rodriguez A., Garcia-Huerta P., et al. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J 2012, 26:1616-1628.
28. Jimenez-Pacheco A., Mesuret G., Sanz-Rodriguez A., Tanaka K., Mooney C., Conroy R., et al. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 2013, 54:1551-1561.
29. Sim J.A., Young M.T., Sung H.Y., North R.A., Surprenant A. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci 2004, 24:6307-6314.
30. Roth T.L., Nayak D., Atanasijevic T., Koretsky A.P., Latour L.L., McGavern D.B. Transcranial amelioration of inflammation and cell death after brain injury. Nature 2014, 505:223-228.
31. Salas E., Carrasquero L.M., Olivos-Ore L.A., Bustillo D., Artalejo A.R., Miras-Portugal M.T., et al. Purinergic P2X7 receptors mediate cell death in mouse cerebellar astrocytes in culture. J Pharmacol Exp Ther 2013, 347:802-815.
32. Pan H.C., Chou Y.C., Sun S.H. P2X R-mediated Ca-independent d-serine release via pannexin-1 of the P2X R-pannexin-1 complex in astrocytes. Glia 2015, 10.1002/glia.22790.
33. Matute C., Torre I., Perez-Cerda F., Perez-Samartin A., Alberdi E., Etxebarria E., et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007, 27:9525-9533.
34. Araki T., Simon R.P., Taki W., Lan J.Q., Henshall D.C. Characterization of neuronal death induced by focally evoked limbic seizures in the C57BL/6 mouse. J Neurosci Res 2002, 69:614-621.
35. Mouri G., Jimenez-Mateos E., Engel T., Dunleavy M., Hatazaki S., Paucard A., et al. Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice. Brain Res 2008, 1213:140-151.
36. Liu G., Gu B., He X.P., Joshi R.B., Wackerle H.D., Rodriguiz R.M., et al. Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron 2013, 79:31-38.
37. Bouilleret V., Ridoux V., Depaulis A., Marescaux C., Nehlig A., Le Gal La Salle G. Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Neuroscience 1999, 89:717-729.
38. Mesuret G., Engel T., Hessel E.V., Sanz-Rodriguez A., Jimenez-Pacheco A., Miras-Portugal M.T., et al. P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage. CNS Neurosci Ther 2014, 20:556-564.
39. Avignone E., Ulmann L., Levavasseur F., Rassendren F., Audinat E. Status epilepticus induces a particular microglial activation state characterized by enhanced purinergic signaling. J Neurosci 2008, 28:9133-9144.
40. Kim J.E., Ryu H.J., Yeo S.I., Kang T.C. P2X7 receptor differentially modulates astroglial apoptosis and clasmatodendrosis in the rat brain following status epilepticus. Hippocampus 2011, 21:1318-1333.
41. Choi H.K., Ryu H.J., Kim J.E., Jo S.M., Choi H.C., Song H.K., et al. The roles of P2X7 receptor in regional-specific microglial responses in the rat brain following status epilepticus. Neurol Sci 2012, 33:515-525.
42. Kim J.E., Kang T.C. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J Clin Invest 2011, 121:2037-2047.
43. Chin R.F., Neville B.G., Peckham C., Wade A., Bedford H., Scott R.C. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008, 7:696-703.
44. Dube C.M., Brewster A.L., Richichi C., Zha Q., Baram T.Z. Fever, febrile seizures and epilepsy. Trends Neurosci 2007, 30:490-496.
45. Lewis D.V., Shinnar S., Hesdorffer D.C., Bagiella E., Bello J.A., Chan S., et al. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study. Ann Neurol 2014, 75:178-185.
46. Emsley H.C., Appleton R.E., Whitmore C.L., Jury F., Lamb J.A., Martin J.E., et al. Variations in inflammation-related genes may be associated with childhood febrile seizure susceptibility. Seizure 2014, 23:457-461.
47. Kahle K.T., Staley K.J., Nahed B.V., Gamba G., Hebert S.C., Lifton R.P., et al. Roles of the cation-chloride cotransporters in neurological disease. Nat Clin Pract Neurol 2008, 4:490-503.
48. Dunleavy M., Shinoda S., Schindler C., Ewart C., Dolan R., Gobbo O.L., et al. Experimental neonatal status epilepticus and the development of temporal lobe epilepsy with unilateral hippocampal sclerosis. Am J Pathol 2010, 176:330-342.
49. Haut S.R., Veliskova J., Moshe S.L. Susceptibility of immature and adult brains to seizure effects. Lancet Neurol 2004, 3:608-617.
50. Bhattacharya A., Wang Q., Ao H., Shoblock J.R., Lord B., Aluisio L., et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 2013, 170:624-640.
51. Garcia-Huerta P., Diaz-Hernandez M., Delicado E.G., Pimentel-Santillana M., Miras-Portugal M.T., Gomez-Villafuertes R. The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system. J Biol Chem 2012, 287:44628-44644.